{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T04:56:51Z","timestamp":1787201811909,"version":"build-2736575974"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006095","name":"Helse S\u00f8r-\u00d8st RHF","doi-asserted-by":"publisher","award":["2021-065"],"award-info":[{"award-number":["2021-065"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005366","name":"University of Oslo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005366","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Thermal ablation of colorectal liver metastases (CRLM) is traditionally reserved for patients who are not candidates for surgical resection, but it is increasingly applied as a parenchyma-sparing alternative. This study investigates long-term outcomes following laparoscopic resection and thermal ablation in a parenchyma-sparing treatment strategy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Cohort study of patients with CRLM treated with laparoscopic resection or thermal ablation at Oslo University Hospital between 2007 and 2020, identified from two prospectively maintained databases. The primary endpoint was the average treatment effect on survival, estimated using inverse probability weighting to adjust for prognostic variables. Secondary endpoints included overall survival and progression-free survival. In case of recurrence of liver metastases after the study treatment, both ablation and resection were used.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 207 ablation procedures and 499 resection procedures were eligible for analysis. Five-year overall survival was 55.2% in the ablation group and 55.1% in the resection group. The estimated average treatment effect of ablation versus resection was \u2212\u20090.34 months (95% confidence interval \u2212\u20097.29 to 6.57;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.919), indicating that treating all patients with ablation would yield an average survival of 0.34 months shorter than treating all patients with resection.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In a parenchymal-sparing paradigm, thermal ablation yields long-term survival comparable to resection for CRLM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-19621-1","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T12:31:06Z","timestamp":1776169866000},"page":"7833-7841","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Long-Term Oncological Outcomes After Laparoscopic Resection and Thermal Ablation of Colorectal Liver Metastases Within a Parenchyma-Sparing Strategy"],"prefix":"10.1245","volume":"33","author":[{"given":"I. Schr\u00f8der","family":"Hansen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. L.","family":"Aghayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Pelanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. I.","family":"R\u00f8sok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. W.","family":"Brudvik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Yaqub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Lassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Bj\u00f8rk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Brabrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Edwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Syversveen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c5. A.","family":"Fretland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"issue":"3","key":"19621_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin."},{"issue":"10","key":"19621_CR2","doi-asserted-by":"publisher","first-page":"761","DOI":"10.5306\/wjco.v11.i10.761","volume":"11","author":"J Martin","year":"2020","unstructured":"Martin J, Petrillo A, Smyth EC, et al. Colorectal liver metastases: Current management and future perspectives. World J Clin Oncol. 2020;11(10):761\u2013808. https:\/\/doi.org\/10.5306\/wjco.v11.i10.761.","journal-title":"World J Clin Oncol."},{"issue":"5","key":"19621_CR3","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.ejso.2019.12.003","volume":"46","author":"M Di Martino","year":"2020","unstructured":"Di Martino M, Rompianesi G, Mora-Guzm\u00e1n I, Mart\u00edn-P\u00e9rez E, Montalti R, Troisi RI. Systematic review and meta-analysis of local ablative therapies for resectable colorectal liver metastases. Eur J Surg Oncol. 2020;46(5):772\u201381. https:\/\/doi.org\/10.1016\/j.ejso.2019.12.003.","journal-title":"Eur J Surg Oncol."},{"issue":"3","key":"19621_CR4","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.ejso.2019.12.002","volume":"46","author":"P Tinguely","year":"2020","unstructured":"Tinguely P, Dal G, Bottai M, Nilsson H, Freedman J, Engstrand J. Microwave ablation versus resection for colorectal cancer liver metastases: a propensity score analysis from a population-based nationwide registry. Eur J Surg Oncol. 2020;46(3):476\u201385. https:\/\/doi.org\/10.1016\/j.ejso.2019.12.002.","journal-title":"Eur J Surg Oncol."},{"key":"19621_CR5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ejca.2023.03.038","volume":"187","author":"P Tinguely","year":"2023","unstructured":"Tinguely P, Ruiter SJS, Engstrand J, et al. A prospective multicentre trial on survival after Microwave Ablation VErsus Resection for Resectable Colorectal liver metastases (MAVERRIC). Eur J Cancer. 2023;187:65\u201376. https:\/\/doi.org\/10.1016\/j.ejca.2023.03.038.","journal-title":"Eur J Cancer."},{"issue":"5","key":"19621_CR6","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1007\/s11605-014-2461-0","volume":"18","author":"KM Govaert","year":"2014","unstructured":"Govaert KM, van Kessel CS, Steller EJ, et al. Recurrence location after resection of colorectal liver metastases influences prognosis. J Gastrointest Surg. 2014;18(5):952\u201360. https:\/\/doi.org\/10.1007\/s11605-014-2461-0.","journal-title":"J Gastrointest Surg."},{"issue":"2","key":"19621_CR7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/s1470-2045(24)00660-0","volume":"26","author":"S van der Lei","year":"2025","unstructured":"van der Lei S, Puijk RS, Dijkstra M, et al. Thermal ablation versus surgical resection of small-size colorectal liver metastases (COLLISION): an international, randomised, controlled, phase 3 non-inferiority trial. Lancet Oncol. 2025;26(2):187\u201399. https:\/\/doi.org\/10.1016\/s1470-2045(24)00660-0.","journal-title":"Lancet Oncol."},{"key":"19621_CR8","doi-asserted-by":"publisher","unstructured":"Hallet J, Sa Cunha A, Adam R, et al. Factors influencing recurrence following initial hepatectomy for colorectal livermetastases. Br J Surg. 2016;103(10):1366\u201376. https:\/\/doi.org\/10.1002\/bjs.10191.","DOI":"10.1002\/bjs.10191"},{"key":"19621_CR9","doi-asserted-by":"crossref","unstructured":"Allard MA, Adam R. Repeat Hepatectomy for Colorectal Liver Metastases. In: Vauthey J-N, Kawaguchi Y, Adam R, eds. Colorectal Liver Metastasis. Springer International Publishing; 2022:265-276.","DOI":"10.1007\/978-3-031-09323-4_30"},{"issue":"1","key":"19621_CR10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/ckj\/sfab158","volume":"15","author":"NC Chesnaye","year":"2022","unstructured":"Chesnaye NC, Stel VS, Tripepi G, et al. An introduction to inverse probability of treatment weighting in observational research. Clin Kidney J. 2022;15(1):14\u201320. https:\/\/doi.org\/10.1093\/ckj\/sfab158.","journal-title":"Clin Kidney J."},{"issue":"11","key":"19621_CR11","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/j.jvir.2014.08.027","volume":"25","author":"M Ahmed","year":"2014","unstructured":"Ahmed M, Solbiati L, Brace CL, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria\u2013a 10-year update. J Vasc Interv Radiol. 2014;25(11):1691-705.e4. https:\/\/doi.org\/10.1016\/j.jvir.2014.08.027.","journal-title":"J Vasc Interv Radiol."},{"issue":"1","key":"19621_CR12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1515\/raon-2017-0046","volume":"52","author":"DL Aghayan","year":"2018","unstructured":"Aghayan DL, Pelanis E, Avdem Fretland \u00c5, et al. Laparoscopic parenchyma-sparing liver resection for colorectal metastases. Radiol Oncol. 2018;52(1):36\u201341. https:\/\/doi.org\/10.1515\/raon-2017-0046.","journal-title":"Radiol Oncol."},{"issue":"3","key":"19621_CR13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1089\/10926420152389260","volume":"11","author":"B Edwin","year":"2001","unstructured":"Edwin B, Mala T, Gladhaug I, et al. Liver tumors and minimally invasive surgery: a feasibility study. J Laparoendosc Adv Surg Tech A. 2001;11(3):133\u20139. https:\/\/doi.org\/10.1089\/10926420152389260.","journal-title":"J Laparoendosc Adv Surg Tech A."},{"issue":"2","key":"19621_CR14","doi-asserted-by":"publisher","first-page":"175","DOI":"10.7326\/m20-4011","volume":"174","author":"DL Aghayan","year":"2021","unstructured":"Aghayan DL, Kazaryan AM, Dagenborg VJ, et al. Long-term oncologic outcomes after laparoscopic versus open resection for colorectal liver metastases: a randomized trial. Ann Intern Med. 2021;174(2):175\u201382. https:\/\/doi.org\/10.7326\/m20-4011.","journal-title":"Ann Intern Med."},{"issue":"10","key":"19621_CR15","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/s1470-2045(22)00506-x","volume":"23","author":"BL Ecker","year":"2022","unstructured":"Ecker BL, Lee J, Saadat LV, et al. Recurrence-free survival versus overall survival as a primary endpoint for studies of resected colorectal liver metastasis: a retrospective study and meta-analysis. Lancet Oncol. 2022;23(10):1332\u201342. https:\/\/doi.org\/10.1016\/s1470-2045(22)00506-x.","journal-title":"Lancet Oncol."},{"issue":"4","key":"19621_CR16","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s11605-021-05173-0","volume":"26","author":"Y Nishioka","year":"2022","unstructured":"Nishioka Y, Paez-Arango N, Boettcher FO, et al. Neither surgical margin status nor somatic mutation predicts local recurrence after R0-intent resection for colorectal liver metastases. J Gastrointest Surg. 2022;26(4):791\u2013801. https:\/\/doi.org\/10.1007\/s11605-021-05173-0.","journal-title":"J Gastrointest Surg."},{"key":"19621_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(25)00024-x","author":"BC Odisio","year":"2025","unstructured":"Odisio BC, Albuquerque J, Lin YM, et al. Software-based versus visual assessment of the minimal ablative margin in patients with liver tumours undergoing percutaneous thermal ablation (COVER-ALL): a randomised phase 2 trial. Lancet Gastroenterol Hepatol. 2025. https:\/\/doi.org\/10.1016\/s2468-1253(25)00024-x.","journal-title":"Lancet Gastroenterol Hepatol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19621-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-19621-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19621-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T15:49:06Z","timestamp":1786204146000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-19621-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":17,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["19621"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-19621-1","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"assertion":[{"value":"13 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Fretland has the following disclosures: Bayer (speaker), Olympus (speaker), Angiodynamics (speaker), Medtronic (speaker), Siemens Healthineers (institutional). Dr. R\u00f8sok has the following disclosures: Amgen (speaker), Eisai (speaker), Astra Zeneca (speaker), Angiodynamics (speaker), Sirtex (speaker). Prof. Edwin has the following disclosures: Medtronic (speaker), Olympus (speaker). Dr. Bj\u00f6rk - Paid presentation for GE about the contrast media Sonazoid at Nordic congress of Radiology in May 2025.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}}]}}